OncoX inks licensing deal worth over $26m for NSCLC therapy
OncoX will pay an upfront cost of $12.5m in cash and shares for rights to ABVC’s non-small cell lung cancer therapy, BLEX 404.
OncoX will pay an upfront cost of $12.5m in cash and shares for rights to ABVC’s non-small cell lung cancer therapy, BLEX 404.